PHAR (Pharming Group) Marketable Securities: $117.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHAR Pharming Group PHAR
77 GF Score
Price $13.47
GF Value $14.45
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Marketable Securities?

Pharming Group PHAR +2.98% 77 Marketable Securities is $117.8 Mil as of Mar. 2026. GuruFocus rates PHAR with a GF Score™ of 77/100 and a GF Value™ of $14.45 (Fairly Valued). The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Pharming Group's Marketable Securities for the quarter that ended in Mar. 2026 was $117.8 Mil.

Pharming Group's annual Marketable Securities declined from Dec. 2023 ($151.7 Mil) to Dec. 2024 ($112.9 Mil) and declined from Dec. 2024 ($112.9 Mil) to Dec. 2025 ($33.8 Mil).

Pharming Group  (NAS:PHAR) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Pharming Group Marketable Securities Related Terms

Pharming Group Marketable Securities Historical Data

* Premium members only.

The historical data trend for Pharming Group's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Marketable Securities Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 151.68 112.95 33.80

Pharming Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.18 33.92 33.80 33.80 117.80
PHAR
77GF Score
Pharming Group PHAR
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $117.8 Mil mean?
Pharming Group (PHAR) has a Marketable Securities of $117.8 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pharming Group and its competitors.
Is Pharming Group's Marketable Securities too high?
Pharming Group's current Marketable Securities is $117.8 Mil. Overall, Pharming Group has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Marketable Securities compare to VRTX and REGN?
Pharming Group's Marketable Securities of $117.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pharming Group and its competitors. Pharming Group's current Marketable Securities is $117.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.45, compared to a current price of $13.47 — trading 6.8% below its estimated fair value. The current Marketable Securities is $117.8 Mil. Pharming Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Pharming Group (PHAR), the current Marketable Securities is $117.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.47 is trading 6.8% below its estimated GF Value™ of $14.45. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • Marketable Securities: $117.8 Mil
  • GF Value™: $14.45 vs. price of $13.47 (6.8% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
77GF Score

Get the complete analysis for PHAR

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.47
Price
$14.45
GF Value